Fast Five Quiz: Alzheimer's Disease Management

Jasvinder P. Chawla, MD, MBA; Shaheen E. Lakhan, MD, PhD, MS, MEd


December 21, 2022

Combination therapy with memantine and ChEIs has been found to delay institutionalization in patients with moderate to severe Alzheimer's disease. In addition to memantine and ChEIs, rivastigmine (13.3 mg/24 hours) showed improved function and cognition compared with traditional lower dosing (4.6 mg/24 hours).

Creative art classes, antipsychotic medications, increased video game time, < 6 hours of sleep nightly, and treatment with gabapentin 300 mg orally three times daily typically do not delay institutionalization of patients with moderate to severe Alzheimer's disease.

Learn more about memantine and ChEIs for patients with Alzheimer's disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.